Natixis Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.56M | Buy |
72,178
+9,283
| +15% | +$200K | ﹤0.01% | 1166 |
|
|
2025
Q1 | $1.05M | Buy |
62,895
+15,888
| +34% | +$264K | ﹤0.01% | 1262 |
|
|
2024
Q4 | $863K | Buy |
47,007
+6,519
| +16% | +$120K | ﹤0.01% | 1347 |
|
|
2024
Q3 | $623K | Buy |
40,488
+14,961
| +59% | +$230K | ﹤0.01% | 1414 |
|
|
2024
Q2 | $415K | Buy |
25,527
+7,697
| +43% | +$125K | ﹤0.01% | 1471 |
|
|
2024
Q1 | $330K | Sell |
17,830
-23,045
| -56% | -$427K | ﹤0.01% | 1464 |
|
|
2023
Q4 | $1.28M | Buy |
40,875
+6,112
| +18% | +$191K | ﹤0.01% | 1138 |
|
|
2023
Q3 | $724K | Buy |
34,763
+9,676
| +39% | +$202K | ﹤0.01% | 1257 |
|
|
2023
Q2 | $601K | Buy |
25,087
+11,110
| +79% | +$266K | ﹤0.01% | 1293 |
|
|
2023
Q1 | $263K | Buy |
+13,977
| New | +$263K | ﹤0.01% | 1425 |
|